RESEARCH · NAD+ 500MG · IMMUNOMETABOLISM
NAD+ and Macrophages: CD38, NAMPT Salvage and De Novo Synthesis in Immune-Cell and Inflammaging Research
PurixLab’s NAD+ 500mg product is nicotinamide adenine dinucleotide, the coenzyme that carries electrons in glycolysis and mitochondrial respiration and is also consumed as a substrate by sirtuins, PARPs and NAD hydrolases. Earlier articles in this series covered core coenzyme biology, membrane transport and age-related decline in human tissue. This overview takes a narrower angle: what laboratory studies report about how macrophages and other immune cells make, recycle and break down NAD+. Most of this work used mouse models, cultured cell lines and primary cells. The findings are described as the authors reported them. They are not claims about any PurixLab product, and the material is for laboratory research use only.
Why immune cells are a useful NAD+ model
Activated immune cells change their metabolism quickly, and several of the enzymes that set cellular NAD+ levels are strongly regulated during inflammation. A 2021 review describes NAMPT, the salvage-pathway enzyme that recovers NAD+ from nicotinamide, as generating most of the cellular NAD+ pool, and notes that NAD hydrolases such as CD38 appear to be extensively involved in the immune response [1]. Macrophages therefore let researchers watch synthesis, salvage and consumption shift within hours of a defined stimulus, often lipopolysaccharide (LPS). Three questions run through the literature: where macrophage NAD+ comes from, why inflammatory macrophages lean on salvage, and how NAD-consuming immune cells might affect NAD+ levels in surrounding tissue.
De novo synthesis from tryptophan
NAD+ can be made from scratch from tryptophan through the kynurenine pathway, ending with the conversion of quinolinate. Minhas and colleagues used isotope tracer studies and reported that macrophage NAD+ derives substantially from kynurenine-pathway metabolism of tryptophan [2]. Genetic or pharmacological blockade of this de novo route depleted NAD+, suppressed mitochondrial NAD+-dependent signalling and respiration, and impaired phagocytosis and resolution of inflammation in their models [2].
The same study described an apparent paradox. Innate immune challenge activated the upstream kynurenine pathway yet suppressed cell-autonomous NAD+ synthesis, because less downstream quinolinate was converted to NAD+. The authors reported a similar profile in aging macrophages, and that increasing de novo NAD+ generation in immune-challenged or aged macrophages restored oxidative phosphorylation in their experiments [2]. They proposed, as a hypothesis, that a breakdown of de novo synthesis may contribute to declining NAD+ and innate immune dysfunction with age.
NAMPT salvage after inflammatory activation
A second line of work focuses on the salvage pathway. Cameron and colleagues reported that NAD+ depletion and increased NAMPT expression occurred rapidly after inflammatory activation of macrophages [3]. In their account, reactive oxygen species from complex III of the mitochondrial electron-transport chain caused DNA damage, which activated poly(ADP-ribose) polymerase and consumed NAD+. Higher NAMPT expression then maintained NAD+ pools large enough to support glyceraldehyde-3-phosphate dehydrogenase activity and the glycolytic, Warburg-like metabolism of LPS-activated cells [3].
An earlier cell-line study looked at structure rather than cytokines. Venter and colleagues inhibited NAMPT with FK866 in RAW 264.7 and Maf-DKO macrophages [4]. They reported lower cytosolic NAD+ and reduced glycolytic flux without direct effects on viability, ATP production capacity or mitochondrial respiration, together with changes in cell shape, substrate adhesion, spreading and early phagocytosis of zymosan particles. Adding NAD+, NMN or NADP+ back to the culture reversed the inhibitor’s effects in that system [4]. The authors linked cytosolic NAD+ supply to actin-based cytoskeletal dynamics.
Read together, these papers suggest that macrophages draw on both routes, and that the balance may depend on activation state, species and culture conditions. The studies used different cell sources and stimuli, so they should not be merged into a single pathway model.
CD38: an NADase and an inflammatory-macrophage marker
CD38 is a membrane enzyme that hydrolyses NAD+. In a transcriptional comparison of murine macrophage subsets, Jablonski and colleagues validated CD38 as M1-exclusive and reported that CD38 labelled 71% of in vitro M1 macrophages, with a similar CD38-positive population increasing after LPS exposure in vivo [5]. The same group then showed that CD38 transcript and protein were robustly induced in human macrophages exposed to LPS, with or without IFN-γ, but not with IL-4 [6]. In primary human macrophages, pharmacological or genetic loss of CD38 reduced IL-6 and IL-12p40 secretion and glycolytic activity [6].
In ageing research, Camacho-Pereira and colleagues reported that CD38 expression and activity increase with age in mice and that CD38 was required for age-related NAD+ decline and mitochondrial dysfunction, partly through SIRT3 [7]. They also identified CD38 as the main enzyme degrading the precursor nicotinamide mononucleotide (NMN) in vivo [7]. That finding matters for study design, because CD38 activity in a model can change how much of an added precursor survives.
Senescent cells, macrophages and tissue NAD+
Two papers published together in 2020 asked which cells carry the extra CD38. Covarrubias and colleagues reported that pro-inflammatory M1-like macrophages, but not naive or M2 macrophages, accumulate in visceral white adipose tissue and liver during ageing and acute inflammation in mice. These cells expressed high CD38 and had enhanced CD38-dependent NADase activity [8]. Inflammatory factors secreted by senescent cells, the senescence-associated secretory phenotype (SASP), induced macrophages to proliferate and express CD38 [8].
Chini and colleagues reached a similar conclusion from a different direction. They reported that the age-related rise of CD38 in white adipose tissue and liver was mediated by accumulation of CD38-positive immune cells, and that removing senescent cells or their secretory phenotype lowered CD38 and partially reversed NAD+ decline [9]. Blocking the ecto-enzymatic, outward-facing activity of CD38 raised NAD+ through an NMN-dependent process [9]. An earlier study from the same laboratory reported that a thiazoloquin(az)olin(on)e CD38 inhibitor, 78c, reversed age-related NAD+ decline in mouse models of natural and accelerated ageing, and that its physiological effects were reversed when NAD+ synthesis was inhibited [10].
What chronic NAD+ depletion does to a cell
A 2025 cell-culture study looked at the opposite problem: what happens when cells run low on NAD+ for weeks. Removing nicotinamide from the medium of NIH3T3 fibroblasts dropped intracellular NAD+ within 2 days, and the cells stayed viable for 7-14 days with NAD+ below 10% of control levels [11]. The depleted cells showed reduced spare and maximal respiratory capacity, impaired glycolysis and an interferon-dependent inflammatory response resembling viral infection. The authors traced this to leakage of mitochondrial DNA into the cytosol and STING signalling, and saw similar interferon responses in human IMR90 fibroblasts and HS5 stromal cells [11]. For immunometabolism researchers, this links low NAD+ to an innate immune signal even in non-immune cells.
Open questions and study limits
- Mostly mouse and cell-culture data. The de novo synthesis, salvage and senescence-macrophage findings come largely from mice, cell lines and stimulated primary cells [2,3,8,9]. How far they describe human tissue is not settled.
- Stimulus dependence. Many results rely on LPS, sometimes with IFN-γ. Other stimuli and tissue environments may shift macrophages differently [3,6].
- Marker versus driver. CD38 marks inflammatory macrophages, but its weight relative to PARPs, sirtuins and synthesis capacity likely varies by tissue and model [5,7].
- Disclosed interests. Several CD38 papers disclose an author patent on CD38 inhibitors for metabolic diseases and industry consulting [10,9].
- Experimental NAD+ is not the same as cellular NAD+. Adding NAD+ to a culture tests what extracellular NAD+ and its breakdown products do in that system. Where uptake or extracellular degradation matters, researchers usually measure intracellular levels directly rather than assume them.
NAD+ 500mg at PurixLab
NAD+ 500mg: a single-compound research product supplied with a labelled content of 500mg per vial, C$109 per vial (CAD, before tax), supplied for laboratory research only. It is not the material used in the studies above. The product page does not currently show a certificate of analysis. If your project needs particular supporting documentation, email [email protected] before ordering and tell us what you need. Product page: purixlab.com/product/nad-500mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout). Current offers are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Navas LE, Carnero A. NAD(+) metabolism, stemness, the immune response, and cancer. Signal Transduct Target Ther. 2021;6(1):2. PubMed 33384409 · PMC7775471 · doi:10.1038/s41392-020-00354-w
- Minhas PS, Liu L, Moon PK, et al. Macrophage de novo NAD(+) synthesis specifies immune function in aging and inflammation. Nat Immunol. 2019;20(1):50-63. PubMed 30478397 · PMC6768398 · doi:10.1038/s41590-018-0255-3
- Cameron AM, Castoldi A, Sanin DE, et al. Inflammatory macrophage dependence on NAD(+) salvage is a consequence of reactive oxygen species-mediated DNA damage. Nat Immunol. 2019;20(4):420-432. PubMed 30858618 · PMC12842115 · doi:10.1038/s41590-019-0336-y
- Venter G, Oerlemans FT, Willemse M, et al. NAMPT-mediated salvage synthesis of NAD+ controls morphofunctional changes of macrophages. PLoS One. 2014;9(5):e97378. PubMed 24824795 · PMC4019579 · doi:10.1371/journal.pone.0097378
- Jablonski KA, Amici SA, Webb LM, et al. Novel Markers to Delineate Murine M1 and M2 Macrophages. PLoS One. 2015;10(12):e0145342. PubMed 26699615 · PMC4689374 · doi:10.1371/journal.pone.0145342
- Amici SA, Young NA, Narvaez-Miranda J, et al. CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions. Front Immunol. 2018;9:1593. PubMed 30042766 · PMC6048227 · doi:10.3389/fimmu.2018.01593
- Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. PubMed 27304511 · PMC4911708 · doi:10.1016/j.cmet.2016.05.006
- Covarrubias AJ, Kale A, Perrone R, et al. Senescent cells promote tissue NAD(+) decline during ageing via the activation of CD38(+) macrophages. Nat Metab. 2020;2(11):1265-1283. PubMed 33199924 · PMC7908681 · doi:10.1038/s42255-020-00305-3
- Chini CCS, Peclat TR, Warner GM, et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD(+) and NMN levels. Nat Metab. 2020;2(11):1284-1304. PubMed 33199925 · PMC8752031 · doi:10.1038/s42255-020-00298-z
- Tarragó MG, Chini CCS, Kanamori KS, et al. A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD(+) Decline. Cell Metab. 2018;27(5):1081-1095.e10. PubMed 29719225 · PMC5935140 · doi:10.1016/j.cmet.2018.03.016
- Chini CCS, Colman L, Palmieri E, et al. Chronic Cellular NAD Depletion Activates a Viral Infection-Like Interferon Response Through Mitochondrial DNA Leakage. Aging Cell. 2025;24(9):e70135. PubMed 40519092 · PMC12419838 · doi:10.1111/acel.70135